DMD054031 1975..1993
暂无分享,去创建一个
R. Obach | L. Di | B. Feng | T. Goosen | Y. Lai | S. Steyn | M. Varma | Stefanus J. Steyn | Yurong Lai | R. S. Obach | Li Di | Bo Feng | Theunis C. Goosen | Stefanus J. Steyn | Manthena V. Varma
[1] Sarfaraz K. Niazi. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2004, Handbook of Pharmaceutical Manufacturing Formulations, Third Edition.
[2] Karen Rowland-Yeo,et al. Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans , 2013, Xenobiotica; the fate of foreign compounds in biological systems.
[3] S. Haddad,et al. Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data. , 2013, Journal of pharmaceutical sciences.
[4] Karen Rowland-Yeo,et al. Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling , 2013, Clinical Pharmacokinetics.
[5] H. Ellens,et al. Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations , 2013, Expert opinion on drug metabolism & toxicology.
[6] Jian Lin,et al. Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin , 2013, Drug Metabolism and Disposition.
[7] Hugh A Barton,et al. Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond , 2013, Expert opinion on drug metabolism & toxicology.
[8] B. Feng,et al. Response to the Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions” , 2013, Pharmaceutical Research.
[9] A. D. Rodrigues,et al. Cynomolgus Monkey as a Potential Model to Assess Drug Interactions Involving Hepatic Organic Anion Transporting Polypeptides: In Vitro, In Vivo, and In Vitro-to-In Vivo Extrapolation , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[10] Franco Lombardo,et al. Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State , 2013, Journal of clinical pharmacology.
[11] Franco Lombardo,et al. Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance , 2013, Journal of clinical pharmacology.
[12] Malcolm Rowland,et al. Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential , 2012, Pharmaceutical Research.
[13] S. Goutelle,et al. In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates , 2013, The AAPS Journal.
[14] T. Goosen,et al. Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide , 2013, Pharmaceutical Research.
[15] Malcolm Rowland,et al. Tissue lipids and drug distribution: dog versus rat. , 2012, Journal of pharmaceutical sciences.
[16] R. Obach,et al. Statistical Methods for Analysis of Time-Dependent Inhibition of Cytochrome P450 Enzymes , 2012, Drug Metabolism and Disposition.
[17] K. Maeda,et al. Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. , 2012, Molecular pharmaceutics.
[18] C. Hilgendorf,et al. Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1 , 2012, Clinical pharmacology and therapeutics.
[19] Christopher E. Keefer,et al. Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. , 2012, European journal of medicinal chemistry.
[20] Aleksandra Galetin,et al. Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes , 2012, Drug Metabolism and Disposition.
[21] Li Di,et al. A Novel Relay Method for Determining Low-Clearance Values , 2012, Drug Metabolism and Disposition.
[22] D. Surry,et al. Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[23] T. Akabane,et al. A quantitative approach to hepatic clearance prediction of metabolism by aldehyde oxidase using custom pooled hepatocytes , 2012, Xenobiotica; the fate of foreign compounds in biological systems.
[24] B. Feng,et al. Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion , 2012, Drug Metabolism and Disposition.
[25] J. Houston,et al. Utility of Drug Depletion-Time Profiles in Isolated Hepatocytes for Accessing Hepatic Uptake Clearance: Identifying Rate-Limiting Steps and Role of Passive Processes , 2012, Drug Metabolism and Disposition.
[26] The Development, Characterization, and Application of an OATP1B1 Inhibition Assay in Drug Discovery , 2012, Drug Metabolism and Disposition.
[27] A. Rostami-Hodjegan,et al. Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.
[28] M Rowland,et al. Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions , 2012, Clinical pharmacology and therapeutics.
[29] Lawrence X. Yu,et al. Prediction of volume of distribution at steady state in humans: comparison of different approaches , 2012, Expert opinion on drug metabolism & toxicology.
[30] K. Maeda,et al. Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies , 2012, Clinical pharmacology and therapeutics.
[31] H. Barton,et al. In Vitro Evaluation of Hepatic Transporter-Mediated Clinical Drug-Drug Interactions: Hepatocyte Model Optimization and Retrospective Investigation , 2012, Drug Metabolism and Disposition.
[32] B. Feng,et al. Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions , 2012, Pharmaceutical Research.
[33] L. Tremaine,et al. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development , 2012, Expert opinion on drug metabolism & toxicology.
[34] Hugh A. Barton,et al. Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.
[35] L. Berezhkovskiy. On the accuracy of determination of unbound drug fraction in tissue using diluted tissue homogenate. , 2012, Journal of pharmaceutical sciences.
[36] I. Tamai. Oral drug delivery utilizing intestinal OATP transporters. , 2012, Advanced drug delivery reviews.
[37] Li Di,et al. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. , 2012, Molecular pharmaceutics.
[38] Yuan Chen,et al. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies , 2012, Biopharmaceutics & drug disposition.
[39] M Rowland,et al. The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review , 2012, Clinical pharmacology and therapeutics.
[40] Jan Snoeys,et al. From preclinical to human – prediction of oral absorption and drug–drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example , 2012, Biopharmaceutics & drug disposition.
[41] Yongling Xiao,et al. Differential Modulation of Cytochrome P450 Activity and the Effect of 1-Aminobenzotriazole on Hepatic Transport in Sandwich-Cultured Human Hepatocytes , 2012, Drug Metabolism and Disposition.
[42] Takashi Baba,et al. Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. , 2012, Analytical chemistry.
[43] Dennis A. Smith. Pfizer Sandwich Laboratories: where drug metabolism first met drug discovery , 2012, Xenobiotica; the fate of foreign compounds in biological systems.
[44] Tetsuya Terasaki,et al. Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities , 2012, Drug Metabolism and Disposition.
[45] K. Saleh,et al. Comprehensive assessment. , 2012, Nursing older people.
[46] France Mentré,et al. Optimal Sampling Times for a Drug and its Metabolite using SIMCYP® Simulations as Prior Information , 2012, Clinical Pharmacokinetics.
[47] G. Camenisch,et al. Novel In Vitro-In Vivo Extrapolation (IVIVE) Method to Predict Hepatic Organ Clearance in Rat , 2011, Pharmaceutical Research.
[48] L. Berry,et al. Species Differences in Distribution and Prediction of Human Vss from Preclinical Data , 2011, Drug Metabolism and Disposition.
[49] Li Di,et al. Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.
[50] Y Kumagai,et al. Identification of the Rate‐Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study , 2011, Clinical pharmacology and therapeutics.
[51] Malcolm Rowland,et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. , 2011, Journal of pharmaceutical sciences.
[52] Aleksandra Galetin,et al. Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs , 2011, Drug Metabolism and Disposition.
[53] K. Maeda,et al. Culture Period-Dependent Changes in the Uptake of Transporter Substrates in Sandwich-Cultured Rat and Human Hepatocytes , 2011, Drug Metabolism and Disposition.
[54] D. B. Duignan,et al. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. , 2011, Molecular pharmaceutics.
[55] M. Jamei,et al. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[56] Robert J Riley,et al. Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption , 2011, Drug Metabolism and Disposition.
[57] Hannah M Jones,et al. Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling , 2011, Clinical pharmacokinetics.
[58] Aleksandra Galetin,et al. Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data , 2011, Drug Metabolism and Disposition.
[59] Yuan Chen,et al. Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450 , 2011, Drug Metabolism and Disposition.
[60] A. Hill,et al. Estimating unbound volume of distribution and tissue binding by in vitro HPLC-based human serum albumin and immobilised artificial membrane-binding measurements. , 2011, Journal of pharmaceutical sciences.
[61] G. S. Walker,et al. Validation of Isolated Metabolites from Drug Metabolism Studies as Analytical Standards by Quantitative NMR , 2011, Drug Metabolism and Disposition.
[62] P. Neuvonen,et al. Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.
[63] L Zhang,et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.
[64] Ruili Huang,et al. Identification of Clinically Used Drugs That Activate Pregnane X Receptors , 2011, Drug Metabolism and Disposition.
[65] D. B. Duignan,et al. Characterization of Digoxin Uptake in Sandwich-Cultured Human Hepatocytes , 2011, Drug Metabolism and Disposition.
[66] Amin Rostami-Hodjegan,et al. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. , 2009, British journal of clinical pharmacology.
[67] Yuichi Sugiyama,et al. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[68] Haiyan Li,et al. Contribution of molecular properties to extrapolation of the volume of distribution in human from preclinical animal species data , 2010, Biopharmaceutics & drug disposition.
[69] Y. Mizuki,et al. Prediction of the Intestinal First-Pass Metabolism of CYP3A Substrates in Humans Using Cynomolgus Monkeys , 2010, Drug Metabolism and Disposition.
[70] Sean Ekins,et al. Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties , 2010, Drug Metabolism and Disposition.
[71] Jianghong Fan,et al. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. , 2010, Current drug metabolism.
[72] Y. Sugiyama,et al. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. , 2010, Current drug metabolism.
[73] A Rostami-Hodjegan,et al. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.
[74] Sharon L Ripp,et al. Evaluation of models for predicting drug–drug interactions due to induction , 2010, Expert opinion on drug metabolism & toxicology.
[75] Hiroshi Yamazaki,et al. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. , 2010, Current drug metabolism.
[76] R. Obach,et al. Cytochrome P450 3A4 mRNA Is a More Reliable Marker than CYP3A4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing Enzymes , 2010, Drug Metabolism and Disposition.
[77] Kuresh Youdim,et al. In Vitro-In Vivo Correlation for Intrinsic Clearance for Drugs Metabolized by Human Aldehyde Oxidase , 2010, Drug Metabolism and Disposition.
[78] J. Houston,et al. Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View , 2010, Pharmaceutical Research.
[79] F. Lombardo,et al. Use of the Øie-Tozer Model in Understanding Mechanisms and Determinants of Drug Distribution , 2010, Drug Metabolism and Disposition.
[80] Michael Gertz,et al. Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.
[81] Ying-Hong Wang,et al. Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors , 2010, Drug Metabolism and Disposition.
[82] D. B. Duignan,et al. Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools , 2010, Xenobiotica; the fate of foreign compounds in biological systems.
[83] Y. Lai,et al. Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. , 2010, Molecular pharmaceutics.
[84] Masoud Jamei,et al. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[85] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[86] R Scott Obach,et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. , 2010, Journal of medicinal chemistry.
[87] V. Kumar,et al. Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data , 2008, European Journal of Drug Metabolism and Pharmacokinetics.
[88] Gary W. Caldwell,et al. Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted fromin-vivo rat data? , 2004, European Journal of Drug Metabolism and Pharmacokinetics.
[89] A. Guillouzo,et al. General review on in vitro hepatocyte models and their applications. , 2010, Methods in molecular biology.
[90] Guideline on the Investigation of Drug Interactions , 2010 .
[91] J. Beijnen,et al. Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam , 2009, Drug Metabolism and Disposition.
[92] S. Yamashita,et al. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. , 2009, Journal of pharmaceutical sciences.
[93] Y. Lai,et al. Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion , 2009, Expert opinion on drug metabolism & toxicology.
[94] Alex Phipps,et al. Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction , 2009, Drug Metabolism and Disposition.
[95] Marilyn E. Morris,et al. Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structure–Pharmacokinetic Relationships , 2009, The AAPS Journal.
[96] Kazuya Maeda,et al. Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments , 2009, Drug Metabolism and Disposition.
[97] Vikram Sinha,et al. In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective , 2009, Drug Metabolism and Disposition.
[98] Leslie Z. Benet,et al. The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.
[99] Franco Lombardo,et al. In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. , 2009, Journal of medicinal chemistry.
[100] Peter J H Webborn,et al. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. , 2009, Molecular pharmaceutics.
[101] Bill J Smith,et al. Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches , 2009, Journal of clinical pharmacology.
[102] M Jamei,et al. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. , 2009, Current drug metabolism.
[103] Claire Strain-Damerell,et al. Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions , 2009, Drug Metabolism and Disposition.
[104] Yuichi Sugiyama,et al. Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development , 2009, The AAPS Journal.
[105] Leslie Z. Benet,et al. Effects of Drug Transporters on Volume of Distribution , 2009, The AAPS Journal.
[106] Sebastian Polak,et al. Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.
[107] B. Långström,et al. Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport , 2009, Drug Metabolism and Disposition.
[108] Kairui Feng,et al. The Simcyp® Population-based ADME Simulator , 2009 .
[109] Caroline A. Lee,et al. Drug–Drug Interactions Mediated Through P‐Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug , 2009, Clinical pharmacology and therapeutics.
[110] Kazuya Maeda,et al. Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.
[111] Aleksandra Galetin,et al. Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes , 2009, Drug Metabolism and Disposition.
[112] Kairui Feng,et al. The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.
[113] Dennis A Smith,et al. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? , 2009, Current opinion in drug discovery & development.
[114] R. Obach. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. , 2009, Current opinion in drug discovery & development.
[115] Yuichi Sugiyama,et al. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. , 2009, Drug metabolism and pharmacokinetics.
[116] M. Niemi,et al. Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism , 2008, Clinical pharmacology and therapeutics.
[117] Meng Li,et al. Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[118] K. Brouwer,et al. In Vitro Biliary Clearance of Angiotensin II Receptor Blockers and 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors in Sandwich-Cultured Rat Hepatocytes: Comparison with in Vivo Biliary Clearance , 2008, Journal of Pharmacology and Experimental Therapeutics.
[119] J. Sahi,et al. Current Industrial Practices in Assessing CYP450 Enzyme Induction: Preclinical and Clinical , 2008, The AAPS Journal.
[120] Tristan S. Maurer,et al. A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro , 2008, Drug Metabolism and Disposition.
[121] Rikiya Ohashi,et al. Effect of Plasma Protein Binding on in Vitro-in Vivo Correlation of Biliary Excretion of Drugs Evaluated by Sandwich-Cultured Rat Hepatocytes , 2008, Drug Metabolism and Disposition.
[122] J. Houston,et al. Rate-Limiting Steps in Hepatic Drug Clearance: Comparison of Hepatocellular Uptake and Metabolism with Microsomal Metabolism of Saquinavir, Nelfinavir, and Ritonavir , 2008, Drug Metabolism and Disposition.
[123] W. Heizer,et al. A novel method for the determination of biliary clearance in humans , 2004, The AAPS Journal.
[124] K. Thummel. Gut instincts: CYP3A4 and intestinal drug metabolism. , 2007, The Journal of clinical investigation.
[125] H. Einolf. Comparison of different approaches to predict metabolic drug–drug interactions , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[126] R J Riley,et al. In vitro–in vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[127] Masoud Jamei,et al. Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.
[128] Manfred Kansy,et al. High throughput solubility measurement in drug discovery and development. , 2007, Advanced drug delivery reviews.
[129] Jochem Alsenz,et al. Development of a partially automated solubility screening (PASS) assay for early drug development. , 2007, Journal of pharmaceutical sciences.
[130] M. Jamei,et al. Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[131] Ken Grime,et al. Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo , 2007, Drug Metabolism and Disposition.
[132] W. Heizer,et al. In Vitro–In Vivo Correlation of Hepatobiliary Drug Clearance in Humans , 2007, Clinical pharmacology and therapeutics.
[133] L J Lesko,et al. Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.
[134] R. Obach. Chapter 30 Prediction of Human Volume of Distribution Using in vivo, in vitro, and in silico Approaches , 2007 .
[135] A. D. Rodrigues,et al. Pharmacokinetic Drug Interactions Involving 17α-Ethinylestradiol , 2007 .
[136] John C Lipscomb,et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.
[137] A. D. Rodrigues,et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. , 2007, Clinical pharmacokinetics.
[138] Malcolm Rowland,et al. Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.
[139] Hans Lennernäs,et al. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[140] Anne Hersey,et al. Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning. , 2006, Journal of medicinal chemistry.
[141] Yuichi Sugiyama,et al. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.
[142] Diana Kazolias,et al. Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport , 2006, Drug Metabolism and Disposition.
[143] Michael Mayersohn,et al. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. , 2006, Journal of pharmaceutical sciences.
[144] Ho-Chul Shin,et al. Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model , 2006, Pharmaceutical Research.
[145] K Rowland-Yeo,et al. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[146] M. Rowland,et al. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.
[147] Mary F Paine,et al. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.
[148] Yuichi Sugiyama,et al. Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[149] Franco Lombardo,et al. A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. , 2006, Journal of medicinal chemistry.
[150] H. Kusuhara,et al. Is the Monkey an Appropriate Animal Model to Examine Drug-Drug Interactions Involving Renal Clearance? Effect of Probenecid on the Renal Elimination of H2 Receptor Antagonists , 2006, Journal of Pharmacology and Experimental Therapeutics.
[151] M Paul Gleeson,et al. In silico human and rat Vss quantitative structure-activity relationship models. , 2006, Journal of medicinal chemistry.
[152] J. Houston,et al. The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.
[153] M. Jamei,et al. Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[154] Alex Avdeef,et al. The rise of PAMPA , 2005, Expert opinion on drug metabolism & toxicology.
[155] M. Varma,et al. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. , 2005, Journal of pharmaceutical sciences.
[156] Kiyomi Ito,et al. IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM , 2005, Drug Metabolism and Disposition.
[157] Mikko Niemi,et al. Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.
[158] M. Rowland,et al. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.
[159] H. Kusuhara,et al. Molecular Cloning and Functional Analyses of OAT1 and OAT3 from Cynomolgus Monkey Kidney , 2005, Pharmaceutical Research.
[160] Tony K L Kiang,et al. UDP-glucuronosyltransferases and clinical drug-drug interactions. , 2005, Pharmacology & therapeutics.
[161] Per Artursson,et al. Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA method , 2005 .
[162] K. Pang,et al. THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING , 2005, Drug Metabolism and Disposition.
[163] Harold Boxenbaum,et al. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics , 1982, Journal of Pharmacokinetics and Biopharmaceutics.
[164] Malcolm Rowland,et al. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[165] Malcolm Rowland,et al. Kinetics of drug-drug interactions , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[166] Robert L. Dedrick,et al. Animal scale-up , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[167] Malcolm Rowland,et al. Clearance concepts in pharmacokinetics , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[168] P. Artursson,et al. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[169] Barry C. Jones,et al. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.
[170] L. Benet,et al. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[171] Vinod Nair,et al. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. , 2004, Current drug metabolism.
[172] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[173] Yoshitaka Yano,et al. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. , 2004, Journal of pharmaceutical sciences.
[174] L. Berezhkovskiy,et al. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. , 2004, Journal of pharmaceutical sciences.
[175] Keith W Ward,et al. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[176] Keith W Ward,et al. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[177] Kim L. R. Brouwer,et al. The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts , 2004, Pharmaceutical Research.
[178] M. Cronin,et al. Quantitative structure‐pharmacokinetic relationship modelling: apparent volume of distribution , 2004, The Journal of pharmacy and pharmacology.
[179] Oliver Burk,et al. Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.
[180] G. Tucker,et al. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[181] M. Machida,et al. Biopharmaceutics Classification by High Throughput Solubility Assay and PAMPA , 2004, Drug development and industrial pharmacy.
[182] Vinod P. Shah,et al. Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.
[183] Paul W. Buehler,et al. Comparison of Oral Absorption and Bioavailability of Drugs Between Monkey and Human , 2002, Pharmaceutical Research.
[184] Hyunyoung Jeong,et al. Evaluation of Using Dog as an Animal Model to Study the Fraction of Oral Dose Absorbed of 43 Drugs in Humans , 2000, Pharmaceutical Research.
[185] A. Barve,et al. Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats , 1998, Pharmaceutical Research.
[186] Hans Lennernäs,et al. Comparison Between Permeability Coefficients in Rat and Human Jejunum , 1996, Pharmaceutical Research.
[187] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[188] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[189] Amy Roe,et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[190] K. Pang,et al. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[191] Scott L Cockroft,et al. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[192] Amin Rostami-Hodjegan,et al. The effects of portal shunts on intestinal cytochrome P450 3A activity , 2002, Hepatology.
[193] Patrick Poulin,et al. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.
[194] Michael Levin. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .
[195] B Agoram,et al. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.
[196] L. Benet,et al. Active secretion and enterocytic drug metabolism barriers to drug absorption. , 2001, Advanced drug delivery reviews.
[197] J. Legendre,et al. Determination of the Aqueous Solubility of Drugs Using a Convenient 96-Well Plate-Based Assay , 2001, Drug development and industrial pharmacy.
[198] F. Russel,et al. Mechanisms and clinical implications of renal drug excretion* , 2001, Drug metabolism reviews.
[199] J S Harmatz,et al. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[200] R. Obach. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[201] C. Bevan,et al. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. , 2000, Analytical chemistry.
[202] K. Pang,et al. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[203] R. Obach,et al. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[204] G L Amidon,et al. A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.
[205] I. Mahmood. Prediction of Clearance, Volume of Distribution and Half‐life by Allometric Scaling and by use of Plasma Concentrations Predicted from Pharmacokinetic Constants: a Comparative Study , 1999, The Journal of pharmacy and pharmacology.
[206] X Liu,et al. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[207] T Lavé,et al. Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations , 1999, Clinical pharmacokinetics.
[208] Y. Sugiyama,et al. Transporters for bile acids and organic anions. , 1999, Pharmaceutical biotechnology.
[209] J. Tolan,et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.
[210] I Mahmood,et al. Interspecies scaling of renally secreted drugs. , 1998, Life sciences.
[211] R. Obach,et al. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[212] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[213] D. Keppler,et al. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. , 1997, Biological chemistry.
[214] M. Müller,et al. Molecular aspects of hepatobiliary transport. , 1997, The American journal of physiology.
[215] R C Chou,et al. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. , 1997, Journal of pharmaceutical sciences.
[216] D. Keppler,et al. Introduction: Transport across the hepatocyte canalicular membrane , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[217] T Ishizaki,et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.
[218] M. Yamazaki,et al. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats. , 1996, Biopharmaceutics & drug disposition.
[219] D. Shen,et al. First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.
[220] T. Ishikawa,et al. How does the MRP/GS-X pump export doxorubicin? , 1996, Journal of the National Cancer Institute.
[221] J. Lin,et al. Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[222] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[223] S. Jezequel. Fluconazole: Interspecies Scaling and Allometric Relationships of Pharmacokinetic Properties , 1994, The Journal of pharmacy and pharmacology.
[224] P. Artursson,et al. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.
[225] P. Artursson,et al. Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.
[226] P. Artursson,et al. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.
[227] J. Mordenti,et al. Man versus beast: pharmacokinetic scaling in mammals. , 1986, Journal of pharmaceutical sciences.
[228] S. Bryson. Clinical Pharmacokinetics: Concepts and applications. , 1983 .
[229] S Oie,et al. Effect of altered plasma protein binding on apparent volume of distribution. , 1979, Journal of pharmaceutical sciences.
[230] G R Wilkinson,et al. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. , 1977, The Journal of pharmacology and experimental therapeutics.
[231] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[232] G R Wilkinson,et al. Commentary: a physiological approach to hepatic drug clearance. , 1975, Clinical pharmacology and therapeutics.
[233] J. Gillette. FACTORS AFFECTING DRUG METABOLISM , 1971, Annals of the New York Academy of Sciences.
[234] Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , Implications for Dosing , and Labeling Recommendations , 2022 .